| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects (NCT04309734) | Atea Pharmaceuticals, Inc. | 2021-10-01 |
| Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) (NCT04235049) | University of Maryland, Baltimore | 2021-10-01 |
| A Community-based Intervention Among Active Drug Users in Montpellier (NCT04008927) | ANRS, Emerging Infectious Diseases | 2020-09-18 |
| Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) (NCT04134767) | April M Young | 2019-11-15 |
| HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST) (NCT04044586) | ANRS, Emerging Infectious Diseases | 2019-09-01 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection (NCT04019717) | Atea Pharmaceuticals, Inc. | 2019-06-20 |
| Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection (NCT03794258) | Humanity & Health Medical Group Limited | 2019-05-01 |
| Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid (NCT04062253) | Hospital Universitario Infanta Leonor | 2019-02-15 |
| Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C (NCT04159246) | Mohamed Saad | 2019-02-10 |
| Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection (NCT03674125) | GeneOne Life Science, Inc. | 2018-09-04 |
| Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection (NCT03588923) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-07-07 |
| PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders (NCT04353986) | Ain Shams University | 2018-06-11 |
| Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study (NCT03461250) | Asociacion para el Estudio del Higado | 2018-04-01 |
| Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (NCT03379506) | Merck Sharp & Dohme LLC | 2018-01-25 |
| Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice (NCT02783976) | Gilead Sciences | 2016-10-28 |
| Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents (NCT03508115) | Corporacion Parc Tauli | 2016-07-28 |
| Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (NCT02707601) | Gilead Sciences | 2016-04-01 |
| Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol (NCT02533427) | Gilead Sciences | 2015-10-29 |
| Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment (NCT02402452) | Gilead Sciences | 2015-05-05 |
| Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment (NCT02397707) | Gilead Sciences | 2015-03-24 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study (NCT01987453) | Gilead Sciences | 2014-07-01 |
| Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency (NCT01958281) | Gilead Sciences | 2013-10-07 |
| Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection (NCT01965535) | Gilead Sciences | 2013-10-01 |
| Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation (NCT01463956) | French National Agency for Research on AIDS and Viral Hepatitis | 2012-01-06 |
| Influence of Nevirapine on HCV Viral Load (NCT01277627) | Valme University Hospital | 2011-01-01 |
| A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (NCT01193478) | Gilead Sciences | 2010-08-01 |
| Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects (NCT01181427) | Abbott | 2010-08-01 |
| Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C (NCT01121185) | MassBiologics | 2010-06-01 |
| Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection (NCT01072695) | Gilead Sciences | 2010-02-01 |
| A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) (NCT00959699) | Merck Sharp & Dohme LLC | 2009-11-01 |
| Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection (NCT00978497) | Hoffmann-La Roche | 2009-09-01 |
| Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir (NCT00931281) | Abbott | 2009-06-01 |
| A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection (NCT01091077) | Massachusetts General Hospital | 2009-06-01 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet (NCT00909636) | Abbott | 2009-05-01 |
| Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection (NCT00874796) | Gilead Sciences | 2009-05-01 |
| Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir (NCT00909311) | Abbott | 2009-05-01 |
| Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers (NCT00895102) | Abbott | 2009-04-01 |
| A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C (NCT00890318) | Abbott | 2009-04-01 |
| Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1 (NCT00850044) | AbbVie | 2009-02-01 |
| Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection (NCT00743795) | Gilead Sciences | 2008-10-01 |
| A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 (NCT00768690) | Abbott | 2008-10-01 |
| A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies (NCT00726882) | AbbVie (prior sponsor, Abbott) | 2008-08-01 |
| Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) (NCT01211626) | Hoffmann-La Roche | 2008-06-01 |
| Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects (NCT00696904) | AbbVie | 2008-06-01 |
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV (NCT00725803) | Gilead Sciences | 2008-04-01 |
| Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection (NCT00623649) | Vertex Pharmaceuticals Incorporated | 2007-11-01 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection (NCT00401947) | Alexion Pharmaceuticals, Inc. | 2006-11-30 |
| Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution. (NCT00213707) | University Hospital, Strasbourg, France | 2003-05-01 |
| MMF Influence on HCV Viral Evolution After Liver Transplantation (NCT00170131) | Mayo Clinic | 2002-09-01 |
| Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients (NCT00221624) | University Hospital, Bordeaux | 2001-11-01 |
| Metabolic Viral Host Properties (NCT00893308) | Hadassah Medical Organization | |